AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS

被引：0
|
作者：
Peer, C. [1 ]
Schmidt, K. [1 ]
Arisa, O. [1 ]
Richardson, W. [1 ]
Paydary, K. [2 ]
Goldstein, D. [3 ,4 ,5 ]
Figg, W. [1 ]
Ratain, M. [2 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
[2] Univ Chicago, Chicago, IL USA
[3] Tel Aviv Univ, Tel Aviv, Israel
[4] Rabin Med Ctr, Davidoff Canc Ctr, Tel Aviv, Israel
[5] Clalit Hlth Serv, Tel Aviv, Israel
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-036
引用
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [1] In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation
    Peer, Cody J.
    Schmidt, Keith T.
    Arisa, Oluwatobi
    Richardson, William J.
    Paydary, Koosha
    Goldstein, Daniel A.
    Gulley, James L.
    Figg, William D.
    Ratain, Mark J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (06): : 672 - 680
  • [2] Pharmacodynamics and pharmacokinetics of natalizumab administered at extended interval dosing
    Ryerson, L. Zhovtis
    Zuniga-Estrada, G.
    Jacob, A.
    Bacon, T.
    Pandey, K.
    Mohn, J.
    Kister, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 917 - 918
  • [3] Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
    Foley, John F.
    Goelz, Susan
    Hoyt, Tamara
    Christensen, Angelene
    Metzger, Ryan R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 65 - 71
  • [4] Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
    Liu, Stephanie N.
    Chan, Phyllis
    Marchand, Mathilde
    Herraez-Baranda, Luis
    Bruno, Rene
    Chanu, Pascal
    Wu, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E44 - E44
  • [5] Model-based simulation to support the extended dosing regimens of atezolizumab
    Chen-Hsi Chou
    Li-Feng Hsu
    European Journal of Clinical Pharmacology, 2021, 77 : 87 - 93
  • [6] Model-based simulation to support the extended dosing regimens of atezolizumab
    Chou, Chen-Hsi
    Hsu, Li-Feng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (01) : 87 - 93
  • [7] Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study
    Monique Bergenwall
    Sandra A. N. Walker
    Marion Elligsen
    Dolores C. Iaboni
    Carla Findlater
    Winnie Seto
    Eugene Ng
    BMC Pediatrics, 19
  • [8] Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation - a retrospective study
    Bergenwall, Monique
    Walker, Sandra A. N.
    Elligsen, Marion
    Iaboni, Dolores C.
    Findlater, Carla
    Seto, Winnie
    Ng, Eugene
    BMC PEDIATRICS, 2019, 19 (01)
  • [9] Extended interval dosing and reduced dose of natalizumab in a Portuguese population
    Marques, P.
    Correia, I.
    Batista, S.
    Nunes, C.
    Macario, C.
    Campelo, I.
    Sousa, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 782 - 783
  • [10] Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
    Ross, Ashley L.
    Tharp, Jennifer L.
    Hobbs, Gerald R.
    McKnight, Richard
    Cumpston, Aaron
    ADVANCES IN PHARMACOLOGICAL SCIENCES, 2013, 2013
12345